<sup>99m</sup>Tc-3PRGD2 SPECT/CT显像用于肺部肿瘤分期及疗效评估的研究进展

孙浩; 张国建; 鲁海文; 王雪梅

doi:10.12122/j.issn.1674-4500.2021.05.27

^99mTc-3PRGD2 SPECT/CT显像用于肺部肿瘤分期及疗效评估的研究进展

doi: 10.12122/j.issn.1674-4500.2021.05.27

孙浩^{1, 2, 3,},
张国建^{1, 2, 3},
鲁海文^{1, 2, 3},
王雪梅^{1, 2, 3, ,}

1.
内蒙古医科大学，内蒙古呼和浩特 010050
2.
内蒙古医科大学附属医院核医学科，内蒙古呼和浩特 010050
3.
内蒙古自治区分子影像学重点实验室，内蒙古呼和浩特 010050

基金项目: 国家自然科学基金(81960319, 61860311);内蒙古自治区科技计划(201502100)

详细信息

作者简介:
孙浩，在读硕士研究生，E-mail: 1149153227@qq.com

通讯作者:
王雪梅，博士，二级教授，主任医师，E- mail: wangxuemei201010@163.com

计量
- 文章访问数: 316
- HTML全文浏览量: 122
- PDF下载量: 22
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-25
- 刊出日期: 2021-09-20

Research progress of ^99mTc-3PRGD2 SPECT/CT in staging and efficacy evaluation of lung tumors

SUN Hao^{1, 2, 3
,},
ZHANG Guojian^{1, 2, 3},
LU Haiwen^{1, 2, 3},
WANG Xuemei^{1, 2, 3
, ,}

1.
Inner Mongolia Medical University, Hohhot 010050, China
2.
Department of Nucleaar Medicine, Affiliated Hospital of Mongolia Medical University, Hohhot 010050, China
3.
Inner Mongolia Key Laboratory of Molecular Imaging, Hohhot 010050, China

Funds: Supported by National Natural Science Foundation of China (81960319, 61860311)

摘要

摘要: 近年来，肺癌发病率逐年上升，也是恶性肿瘤中致死率排名第1位的疾病，晚期患者生存率极低。血管生成和淋巴结转移是恶性肿瘤的两个非常重要的特征，通常认为整合素αvβ3的表达与这两个特征均有关。放射性核素标记的精氨酸-甘氨酸-天冬氨酸肽能与整合素特异的结合，进而可以反映肿瘤血管的变化。达到对肺癌原发灶、转移灶及疗效的早期监测，本文对近年来国内外^99mTc-3PRGD2 SPECT/CT用于肺部肿瘤诊断的研究进展进行综述，主要从^99mTc-3PRGD2显像剂、9mTc-3PRGD2在肺癌原发灶显像方面、^99mTc-3PRGD2 SPECT显像对非小细胞肺癌淋巴结转移监测、^99mTc-3PRGD2 SPECT成像在肺癌患者远处转移的诊断、^99mTc-3PRGD2 SPECT成像在肺癌患者化疗、靶向药物疗效评估等几个方面展开论述。
- ^99mTc-3PRGD2 /
- 整合素 /
- 肺肿瘤 /
- 淋巴结转移 /
- 疗效监测
Abstract: In recent years, the incidence of lung cancer has been increasing year by year, and it is also the most fatal disease among malignant tumors. The survival rate of advanced patients is extremely low. Angiogenesis and lymph node metastasis are two very important characteristics of malignant tumors. It is generally believed that the expression of integrin αvβ3 is related to both of these characteristics. The radionuclide-labeled arginine-glycine-aspartic acid peptide can specifically bind to integrins, which can then reflect the changes in tumor blood vessels. To achieve the early monitoring of lung cancer primary tumors, metastases and efficacy, this article reviews the research progress of ^99mTc-3PRGD2 SPECT/CT in lung tumor diagnosis at home and abroad in recent years.
- ^99mTc-3PRGD2 /
- integrin /
- lung cancer /
- lymph node metastasis /
- effect of monitoring

HTML全文

参考文献(42)

[1]	Jin X, Liang N, Wang M, et al. Integrin Imaging with ^99mTc-3PRGD2 SPECT/CT Shows High Specificity in the Diagnosis of Lymph Node Metastasis from non-small cell lung cancer[J]. Radiology, 2016, 29: 150-63. http://www.researchgate.net/profile/Yunxiao_Meng/publication/305779770_Integrin_Imaging_with_99mTc-3PRGD2_SPECTCT_Shows_High_Specificity_in_the_Diagnosis_of_Lymph_Node_Metastasis_from_Non-Small_Cell_Lung_Cancer/links/584bf78608aeb989251f229b.pdf
[2]	Chen J, Jin G, Yan L, et al. Association between integrin αvβ3 expression and malignancy lymph node metastasis: a meta-analysis[J]. Biomed Res, 2017, 28: 2946-51. http://www.biomedres.info/abstract/association-between-integrin-alphavbeta3-expression-and-malignancy-lymph-node-metastasis-a-metaanalysis-6949.html
[3]	Yue N, Yuan SH, Yang GR. Status and advances of RGD molecular imaging in lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2014, 17(12): 855-9. http://www.lungca.org/index.php?journal=01&page=article&op=download&path[]=10.3779/j.issn.1009-3419.2014.12.06&path[]=4963
[4]	Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-galacto-RGD in cancer patients[J]. J Nucl Med, 2005, 46: 1333-41. http://jnm.snmjournals.org/content/46/8/1333.full.pdf
[5]	Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F] galacto-RGD identifies the level of integrin αvβ3 expression in man[J]. Clin Cancer Res, 2006, 12: 3942-9. doi: 10.1158/1078-0432.CCR-06-0266
[6]	McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers[J]. J Nucl Med, 2008, 49: 1664-7. doi: 10.2967/jnumed.108.052126
[7]	Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp peptide radioligand 18F-AH111585 in breast cancer patients[J]. J Nucl Med, 2008, 49: 879-86. doi: 10.2967/jnumed.107.049452
[8]	Bach-Gansmo T, Danielsson R, Saracco A, et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate ^99mTc-NC100692[J]. J Nucl Med, 2006, 47(9): 1434-9. http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=FC0A2C5E226EADE14AA66ED57AD25943?doi=10.1.1.492.6888&rep=rep1&type=pdf
[9]	Axelsson R, Bach-Gansmo T, Castell-Conesa J, et al. A study to assess the feasibility of imaging metastases in late-stage cancer patients with the αvβ3-selective angiogenesis imaging agent ^99mTc-NC100692[J]. Acta Radiol, 2010, 51: 40-6. doi: 10.3109/02841850903273974
[10]	Liu Z, Li ZB, Cao Q, et al. Small-animal PET of tumors with (64) Culabeled RGD-bombesin heterodimer[J]. Nucl Med, 2009, 50(7): 1168-77. doi: 10.2967/jnumed.108.061739
[11]	Cheng G, Gao S, Ji T, et al. Pharmacokinetics and radiation dosimetry of ^99mTc-3PRGD2 in healthy individuals: a pilot study[J]. Nuclear Sci Techniques, 2012, 23: 349-54. http://www.j.sinap.ac.cn/nst/CN/article/downloadArticleFile.do?attachType=PDF&id=79
[12]	胡骥, 陈宝军, 梁积新, 等. αvβ3受体显像剂99Tcm(N)(PNP6)(Cys-RGD)的制备及动物实验[J]. 同位素, 2007, 20(1): 5-11. doi: 10.3969/j.issn.1000-7512.2007.01.002
[13]	陈宝军, 胡骥, 梁积新, 等. αvβ3受体显像剂99Tcm(N)(PNP6)(Cys-RGD)的制备及动物实验[J]. 同位素, 2007, 20(1): 5-10. doi: 10.3969/j.issn.1000-7512.2007.01.002
[14]	Shi J, Wang L, Kim YS, et al. Improving tumor uptake and excretion kinetics of ^99mTc-labeled cyclic arginine-Glycine-aspartic (RGD) dimers with triglycine linkers[J]. J Med Chem, 2008, 51 (24): 7980-90. doi: 10.1021/jm801134k
[15]	Liu Z, Jia B, Shi J, et al. Tumor uptake of the RGD dimeric probe ^99mTc-G3-2P4-RGD2 is correlated with integrin aVb3 expressed on both tumor cells and neo-vasculature[J]. Bioconjug Chem, 2010, 21: 548-55. doi: 10.1021/bc900547d
[16]	Zhou Y, Kim YS, Chakraborty S, et al. ^99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin aVb3 expression[J]. Mol Imaging, 2011, 10: 386-97. http://smartsearch.nstl.gov.cn/paper_detail.html?id=41496248e1c0512258637a27167924cb
[17]	Jia B, Liu Z, Zhu Z, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer ^99mTc-3PRGD 2 in non-human Primates[J]. Mol Imaging Biol, 2011, 13(4): 730-6. doi: 10.1007/s11307-010-0385-y
[18]	Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using ^99mTc-3P4-RGD2 scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2011, 38: 2145-52. doi: 10.1007/s00259-011-1901-2
[19]	Fukumura D, Jain RK. Imaging angiogenesis and the microenvironment[J]. APMIS, 2008, 116(7/8): 695-715. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859845/pdf/nihms193986.pdf
[20]	马扬. 非小细胞肺癌~(99m)Tc-3PRGD_2 SPECT/CT显像与整合素αvβ3表达的相关性研究[D]. 银川: 宁夏医科大学, 2019.
[21]	NIU LY, LI J, JIA B, et al. Determination of biodistribution of ^99mTc-3PRGD2 in mice bearing the lung carcinoma xenograft by γ counter[J]. IntPharmRes, 2017, 44(8): 705-15. http://en.cnki.com.cn/Article_en/CJFDTOTAL-GWYZ201708011.htm
[22]	Liu ZF, Wang F. Dual-targeted molecular probes for cancer imaging[J]. Curr Pharm Biotechnol, 2010, 11(6): 610-9. doi: 10.2174/138920110792246546
[23]	贺呈祥. 肺占位~(99m)Tc-3PRGD_2 SPECT/CT显像与胸部薄层CT显像的对比研究[D]. 银川: 宁夏医科大学, 2017.
[24]	Antonov AS, Antonova GN, Munn DH, et al. αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation[J]. J Cell Physiol, 2011, 226(2): 469-76. doi: 10.1002/jcp.22356
[25]	Zhang Z, Zhao X, Ding C, et al. (99m)Tc-3PRGD2 SPECT/CT imaging for monitoring early response of EGFR-TKIs therapy in patients with advanced-stage lung adenocarcinoma[J]. Cancer Biother Radiopharm, 2016, 31(7): 238-45. doi: 10.1089/cbr.2016.2052
[26]	Tournoy KG, Keller SM, Annema JT. Mediastinal staging of lung cancer: novel concepts[J]. Lancet Oncol, 2012, 13(5): e221-9. doi: 10.1016/S1470-2045(11)70407-7
[27]	Iskender I, Kapicibasi HO, Kadioglu SZ, et al. Comparison of integrated positron emission tomography/computed tomography and mediastinoscopy in mediastinal staging of non-small cell lung cancer: analysis of 212 patients[J]. Acta Chir Belg, 2012, 112(3): 219-25. doi: 10.1080/00015458.2012.11680827
[28]	van den Hoogen C, van der Horst G, Cheung H, et al. Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer[J]. Am J Pathol, 2011, 179(5): 2559-68. doi: 10.1016/j.ajpath.2011.07.011
[29]	Lv N, Gao S, Bai L, et al. Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer[J]. Ann Nucl Med, 2019, 33(1): 39-46. doi: 10.1007/s12149-018-1300-x
[30]	GAO SM, Qingjie W, Qiang J, et al. ^99mTc-3P_4-RGD_2 radiotracers for SPECT/CT of esophageal tumor[J]. Nucl Sci Tech, 2013, 24(4): 38-43. http://en.cnki.com.cn/Article_en/CJFDTotal-HKXJ201304008.htm
[31]	Miao W, Zheng S, Dai H, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study[J]. PLoS One, 2014, 9(10): e111221-9. doi: 10.1371/journal.pone.0111221
[32]	张召奇, 赵新明. 18F-FDG PET/CT和^99mTc-3PRGD2 SPECT/CT评价晚期肺腺癌靶向治疗及化疗早期疗效的临床研究[D]. 河北: 河北医科大学, 2018.
[33]	吴建国. ^99mTc-3PRGD2生物代谢分布及其在化疗效果监测中的潜在价值[D]. 上海: 上海交通大学, 2014.
[34]	Rayson D, Vantyghem SA, Chambers AF. Angiogenesis as a target for breast cancer therapy[J]. J Mammary Gland Biol Neoplasia, 1999, 4(4): 415-23. doi: 10.1023/A:1018774618873
[35]	Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target[J]. Nature, 2005, 438(7070): 967-74. doi: 10.1038/nature04483
[36]	Rodgers M, Soares M, Epstein D, et al. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer[J]. Health Technol Assess, 2011, 15(Suppl 1): 1-12. doi: 10.3310/hta15suppl1-01
[37]	Sheng J, Yang YP, Yang BJ, et al. Efficacy of addition of antiangiogenic agents to taxanes-containing chemotherapy in advanced nonsmall-cell lung cancer: A meta-analysis and systemic review[J]. Medicine (Baltimore), 2015, 94: 12-82.
[38]	Lee SM, Baas P, Wakelee H. Anti-angiogenesis drugs in lung cancer[J]. Respirology, 2010, 15(3): 387-92. doi: 10.1111/j.1440-1843.2010.01715.x
[39]	Chen B, Zhang W, Ji B, et al. Integrin αVβ3-targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts[J]. Oncol Lett, 2018, 15(4): 4201-6. http://www.onacademic.com/detail/journal_1000040552560710_3d6e.html
[40]	Morrison MS, Ricketts SA, Barnett J, et al. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy[J]. J Nucl Med, 2009, 50(1): 116-22. doi: 10.2967/jnumed.108.056077
[41]	Battle MR, Goggi JL, Allen L, et al. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αvβ3-integrin and αvβ5-integrin imaging agent[J]. Nucl Med, 2011, 52: 424-30. doi: 10.2967/jnumed.110.077479
[42]	Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy[J]. J Nucl Med, 2011, 52(1): 140-6. doi: 10.2967/jnumed.110.080606

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 316
HTML全文浏览量: 122
PDF下载量: 22
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

^99mTc-3PRGD2 SPECT/CT显像用于肺部肿瘤分期及疗效评估的研究进展

doi: 10.12122/j.issn.1674-4500.2021.05.27

作者简介:
孙浩，在读硕士研究生，E-mail: 1149153227@qq.com

通讯作者:
王雪梅，博士，二级教授，主任医师，E- mail: wangxuemei201010@163.com

计量

Research progress of ^99mTc-3PRGD2 SPECT/CT in staging and efficacy evaluation of lung tumors

计量

目录

留言板

99mTc-3PRGD2 SPECT/CT显像用于肺部肿瘤分期及疗效评估的研究进展

doi: 10.12122/j.issn.1674-4500.2021.05.27

作者简介: 孙浩，在读硕士研究生，E-mail: 1149153227@qq.com

通讯作者: 王雪梅，博士，二级教授，主任医师，E- mail: wangxuemei201010@163.com

计量

出版历程

Research progress of 99mTc-3PRGD2 SPECT/CT in staging and efficacy evaluation of lung tumors

计量

出版历程

目录

^99mTc-3PRGD2 SPECT/CT显像用于肺部肿瘤分期及疗效评估的研究进展

作者简介:
孙浩，在读硕士研究生，E-mail: 1149153227@qq.com

通讯作者:
王雪梅，博士，二级教授，主任医师，E- mail: wangxuemei201010@163.com

Research progress of ^99mTc-3PRGD2 SPECT/CT in staging and efficacy evaluation of lung tumors